Citations

Clear

4847 citation(s) found for "Tu, Eric".

Response to the AO Spine/Praxis Spinal Cord Institute guidelines for the management of acute spinal cord injury
Tumialán, Luis M. , Raksin, P B , Shankar, Ganesh M. , Menger, Richard , Bisson, Erica F. , Bydon, Mohamad , Potts, Eric A. , Mullin, Jeffrey P. , Uribe, Juan S.

Mayo Clinic

Journal of Neurosurgery: Spine | January 24, 2025 | Volume: 42 | Issue: 4 | Pages: 530-532

10.3171/2024.8.spine24612 | PMID 39854704 Get It

Letter: AO Spine & Praxis Spinal Cord Institute Clinical Practice Guidelines for the Management of Acute Spinal Cord Injury
Raksin, P B , Prall, J. Adair, Tumialán, Luis M. , Bisson, Erica F. , Bydon, Mohamad , Potts, Eric A. , Raksin, P B , Uribe, Juan S. , Mullin, Jeffrey P.

Mayo Clinic

Neurosurgery | January 24, 2025 | Volume: 96 | Issue: 3 | Pages: e58-e60

10.1227/neu.0000000000003327 | PMID 39853103 Get It

GLP-1RA Use and Thyroid Cancer Risk
Brito, Juan P. , Swarna, Kavya, Ospina, Naykky Singh , Toro-Tobón, David , Deng, Yihong, Mickelson, Mindy M. , Ospina, Naykky Singh , Toro-Tobon, David , Singh Ospina, Naykky , Brito, Juan P , Herrin, Jeph , Montori, Víctor M. , Umpierrez, Guillermo E. , Galindo, Rodolfo J. , Deng, Yihong , Mickelson, Mindy M , Shao, Hui , Polley, Eric C. , McCoy, Rozalina G.

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | January 23, 2025 | Volume: 151 | Issue: 3 | Pages: 243

10.1001/jamaoto.2024.4852 | PMID 39847346 Get It

Importance The increasing use of glucagon-like peptide-1 receptor agonists (GLP-1RA) demands a better understanding of their association with thyroid cancer. Objective To estimate the risk of incident thyroid cancer among adults with type 2 diabetes being treated with GLP-1RA vs other common glucose-lowering medications. Design, Setting, and Participants This was a prespecified secondary analysis of a target trial emulation of a comparative effectiveness study using claims data for enrollees in commercial, Medicare Advantage, and Medicare fee-for-service plans across the US. Eligible participants were adults with type 2 diabetes at moderate risk for cardiovascular disease and without history of thyroid cancer who had newly filled prescriptions for GLP-1RA, sodium-glucose cotransporter 2 inhibitor (SGLT2i), dipeptidyl peptidase-4 inhibitor (DPP4i), or sulfonylurea from January 1, 2014, to December 31, 2021. Data were analyzed February 1 to October 31, 2024. Main Outcomes and Measures Overall and piecewise (<1, 1-2, and ≥2 years since treatment initiation) hazard ratios (HRs) for thyroid cancer with use of GLP-1RA vs the other 3 drug classes were estimated using inverse propensity score weighted Cox proportional hazards models. Modified intention-to-treat (mITT) (primary) and as-treated (sensitivity) analyses were performed. Results Of 351 913 patients (mean [SD] age, 65.3 [8.5] years; 173 391 [49.3%] females and 178 522 [50.7%] males), 41 112 started treatment with GLP-1RA; 76 093, with DPP4i; 43 499, with SGLT2i; and 191 209, with sulfonylurea therapy. The numbers of patients diagnosed with thyroid cancer were 69 (0.17%) in the GLP-1RA group, 172 (0.23%) in the DPP4i group, 72 (0.17%) in the SGLT2i group, and 381 (0.20%) in the sulfonylurea group. In the mITT analysis, GLP-1RA initiation was not significantly associated with increased overall risk for thyroid cancer compared to the other 3 diabetes drugs (HR, 1.24; 95% CI, 0.88-1.76). However, the risk for thyroid cancer was significantly higher within the first year after GLP-1RA initiation (HR, 1.85; 95% CI, 1.11-3.08) and was amplified in the overall as-treated analysis that censored patients when therapy was discontinued or another medication was added (HR, 2.07; 95% CI, 1.10-3.95). Conclusions and Relevance This secondary analysis of a target trial emulation of a comparative effectiveness study found that despite the low absolute risk of thyroid cancer among patients receiving GLP-1RA therapy, there was an increased risk of new thyroid cancer diagnoses within the first year of GLP-1RA initiation compared to 3 other diabetes drugs. This finding may have been due to enhanced early detection; therefore, further research is necessary to understand the underlying causes of this association.
Depressive Symptoms and Amyloid Pathology
Oomens, Julie Elisabeth , Engelborghs, Sebastiaan , Arnim, Christine A. F. Von , Boada, Merçé , Didic, Mira , Dubois, Bruno, Fröhlich, Lutz, Gill, Kiran Dip, Grimmer, Timo, Hildebrandt, Helmut , Itoh, Yoshiaki , Lee, Dong Young , Lleó, Alberto, Meyer, Philipp T. , Kapaki, Elisabeth, Pardini, Matteo , Popp, Julius , Rami, Lorena , Reiman, Eric M. , Rinne, Juha O. , Sánchez‐Juan, Pascual, Sarazin, Marie , Scarmeas, Nikolaos , Villeneuve, Sylvia , Wallin, Anders, Vos, Stephanie J. B. , Jansen, Willemijn J. , group, Amyloid Biomarker Study, Altomare, Daniele , Baldeiras, Inês , Blennow, Kaj, Braber, Anouk den , Cerman, Jiří , Chipi, Elena , Eckerström, Marie , Ekblad, Laura L. , Förster, Stefan , Guedj, Éric , Hausner, Lucrezia , Huey, Edward D. , Jiménez‐Bonilla, J., Johnson, Keith A. , Juaristi, Arantxa, Kern, Silke , Kirsebom, Bjørn‐Eivind , Landau, Susan , Legdeur, Nienke , Guerra, Jorge J. Llibre, Maserejian, Nancy N., Marquié, Marta , Minatani, Shinobu, Olivieri, Pauline , Perrin, Richard J., Peters, Oliver , Prabhakar, Sudesh, Ramakers, Inez H., Rodríguez‐Rodríguez, Eloy , Ruiz, Agustín, Rüther, E., Selnes, Per , Spiru, Luiza , Takeda, Akitoshi , Teichmann, Marc , Thompson, Loisa I., Vogelgsangs, Jonathan, Wallin, Åsa K., Zettergren, Anna , Frisoni, Giovanni B. , Boada, Merce , Oomens, Julie E , Bottlaender, Michel , Wiels, Wietse A. , Baeken, Chris , Dubois, Bruno , Fladby, Tormod , Flier, Wiesje M. van der , Frisoni, Giovanni B. , Fröhlich, Lutz, Grimmer, Timo , Hort, Jakub , Iwatsubo, Takeshi , Klimkowicz‐Mrowiec, Aleksandra , Lleó, Alberto , Martínez‐Lage, Pablo , Mendonça, Alexandre de , Parchi, Piero , Parnetti, Lucilla , Rodrigue, Karen M. , Santana, Isabel , Skoog, Ingmar , Snyder, Peter J. , Sperling, Reisa Anne , Wiltfang, Jens , Zetterberg, Henrik , Ossenkoppele, Rik , Verhey, Frans R.J. , Visser, Pieter Jelle , Alcolea, Daniel , Baiardi, Simone , Bateman, Randall J. , Blennow, Kaj , Buchem, Mark A. van , Byun, Min Soo , Chen, Kewei , Day, Gregory S. , Drzezga, Alexander E. , Epelbaum, Stéphane , Fortea, Juan , Freund‐Levi, Yvonne , Frings, Lars , Hellwig, Sabine , Kandimalla, Ramesh , Paraskevas, George P. , Kornhuber, Johannes , Lagarde, Julien , Morbelli, Silvia , Mroczko, Barbara , Ntanasi, Eva , Oliveira, Catarina Resende , Olivieri, Pauline , Orellana, Adelina , Ruiz, Agustı́n , Silva, Dina , Soininen, Hilkka S. , Tijms, Betty M. , Teunissen, Charlotte E. , Vöglein, Jonathan , Waldemar, Gunhild , Yannakoulia, Mary , Yi, Dahyun

Mayo Clinic

JAMA Psychiatry | January 22, 2025 | Volume: 82 | Issue: 3 | Pages: 296

10.1001/jamapsychiatry.2024.4305 | PMID 39841452 Get It

Importance Depressive symptoms are associated with cognitive decline in older individuals. Uncertainty about underlying mechanisms hampers diagnostic and therapeutic efforts. This large-scale study aimed to elucidate the association between depressive symptoms and amyloid pathology. Objective To examine the association between depressive symptoms and amyloid pathology and its dependency on age, sex, education, and APOE genotype in older individuals without dementia. Design, Setting, and Participants Cross-sectional analyses were performed using data from the Amyloid Biomarker Study data pooling initiative. Data from 49 research, population-based, and memory clinic studies were pooled and harmonized. The Amyloid Biomarker Study has been collecting data since 2012 and data collection is ongoing. At the time of analysis, 95 centers were included in the Amyloid Biomarker Study. The study included 9746 individuals with normal cognition (NC) and 3023 participants with mild cognitive impairment (MCI) aged between 34 and 100 years for whom data on amyloid biomarkers, presence of depressive symptoms, and age were available. Data were analyzed from December 2022 to February 2024. Main Outcomes and Measures Amyloid-β1-42 levels in cerebrospinal fluid or amyloid positron emission tomography scans were used to determine presence or absence of amyloid pathology. Presence of depressive symptoms was determined on the basis of validated depression rating scale scores, evidence of a current clinical diagnosis of depression, or self-reported depressive symptoms. Results In individuals with NC (mean [SD] age, 68.6 [8.9] years; 5664 [58.2%] female; 3002 [34.0%] APOE ε4 carriers; 937 [9.6%] had depressive symptoms; 2648 [27.2%] had amyloid pathology), the presence of depressive symptoms was not associated with amyloid pathology (odds ratio [OR], 1.13; 95% CI, 0.90-1.40; P = .29). In individuals with MCI (mean [SD] age, 70.2 [8.7] years; 1481 [49.0%] female; 1046 [44.8%] APOE ε4 carriers; 824 [27.3%] had depressive symptoms; 1668 [55.8%] had amyloid pathology), the presence of depressive symptoms was associated with a lower likelihood of amyloid pathology (OR, 0.73; 95% CI 0.61-0.89; P = .001). When considering subgroup effects, in individuals with NC, the presence of depressive symptoms was associated with a higher frequency of amyloid pathology in APOE ε4 noncarriers (mean difference, 5.0%; 95% CI 1.0-9.0; P = .02) but not in APOE ε4 carriers. This was not the case in individuals with MCI. Conclusions and Relevance Depressive symptoms were not consistently associated with a higher frequency of amyloid pathology in participants with NC and were associated with a lower likelihood of amyloid pathology in participants with MCI. These findings were not influenced by age, sex, or education level. Mechanisms other than amyloid accumulation may commonly underlie depressive symptoms in late life.
INSIDE-OUT: Introduction of Speakers at IDWeek Events—Observing for Unconscious Bias Over Time
Marcelin, Jasmine R , Lyden, Elizabeth , Abdul‐Mutakabbir, Jacinda C. , Kullar, Ravina , Ristagno, Elizabeth H. , Time), the INSIDE-OUT Study Group (Introduction of Speakers at IDWeek Events—Observing for Unconscious Bias Over, Rajapakse, Nipunie , Patel, Megha, Miller, Amy M. , Oeltjen, Erin N, Semaj, Sophie, Sramek, Kyle T, Lindeman, Christopher J, Daubach, Eric C., Akinmoladun, Oladapo O, Wurtz, Paul J, Ristagno, Elizabeth H , Marcelin, Jasmine , Khazanchi, Rohan , Cawcutt, Kelly , Ha, David R , Florez, Narjust , Time), the INSIDE-OUT Study Group (Introduction of Speakers at IDWeek Events—Observing for Unconscious Bias Over, Patel, Megha, Akinmoladun, Oladapo O., Yang, Yuhong

Mayo Clinic

Open Forum Infectious Diseases | January 17, 2025 | Volume: 12 | Issue: 2 | Pages: No page available

10.1093/ofid/ofaf024 | PMID 39963695 Get It

Abstract Background Specialty societies, including the Infectious Diseases Society of America, strive to address gender and racial inequities in professional advancement. Microaggressions remain a persistent and pervasive barrier to these goals. Nonprofessional speaker introductions are a manifestation of race- and gender-based microaggressions, which have not been previously assessed at IDWeek. We assessed disparities in speaker introductions at IDWeek over a 7-year period that included formal gender equity initiatives introduced in 2016. Methods We conducted a retrospective observational study of video-recorded IDWeek speaker introductions from 2013 to 2019. Trained coders reviewed presentation video archives to assess a primary outcome of nonprofessional introductions: when a speaker's professional title was not used as the first introduction. We used descriptive statistics, Fisher exact tests, Cochrane-Armitage trend tests, and multivariable logistic regression to characterize relationships between speaker introductions and presentation year, speaker demographics, and speaker-moderator demographic concordance. Results Of 1940 videos reviewed, 48.9% of IDWeek speakers received nonprofessional introductions during and before 2016 vs 41.5% of speakers after 2016 (P = .0013). There was an increasing linear trend in the frequency of professional introductions by speaker age group from 47.1% for age <40 years to 65.3% for age >60 years (P < .0001). White moderators more frequently used nonprofessional introductions than moderators from backgrounds underrepresented in medicine (47.7% vs 29.1%, P = .0014). Women-men speaker-moderator pairs had more nonprofessional introductions (54.6%, P < .001). Conclusions In the largest assessment of microaggressions in speaker introductions at a national medical specialty conference, we highlighted some progress over time and ample opportunity to further standardize equitable speaker introductions, especially for women and junior speakers
Palliative Care Initiated in the Emergency Department
Siman, Nina , Adeyemi, Oluwaseun , Yamarik, Rebecca , Investigators, PRIM-ER, Bellolio, Fernanda , Bourenane, Sorayah, Brody, Abraham A. , Cameron, Lauren , Cooper, Julie J. , Deutsch, Ashley, Elsayem, Ahmed , Fleischer-Black, Jessica, Gang, Mauren, Goett, Rebecca , Heaton, Heather A. , Hill, Jacob , Isaacs, Eric, Jubanyik, Karen , Lamba, Sangeeta , Lin, Michelle , Loprinzi-Brauer, Caitlin , Madsen, Troy , Modrek, Ada, Otero, Ronny, Ouchi, Kei , Richardson, Christopher , Richardson, Lynne D. , Schoenfeld, Elizabeth , Shreves, Ashley, Tan, Audrey , Uspal, Julie, Venkat, Arvind , Walker, Laura , Wittman, Ian, Zimny, Erin, Miller, Joseph , Heaton, Heather, Bellolio, M Fernanda , Schoenfeld, Elizabeth M , Grudzen, Corita R. , Cuthel, Allison M. , Goldfeld, Keith S. , Investigators, PRIM-ER, Abella, Benjamin S. , Chodosh, Joshua , Elie, Marie‐Carmelle , Fernandez, Rosemarie , Gang, Mauren, Genes, Nicholas , Horwitz, Leora Idit , Lawrence, Katharine , Miller, Joseph S. A. , Ryan, Matthew, Shaw, Matthew, Southerland, Lauren T.

Mayo Clinic

JAMA | January 15, 2025 | Volume: 333 | Issue: 7 | Pages: 599

10.1001/jama.2024.23696 | PMID 39813042 Get It

Importance The emergency department (ED) offers an opportunity to initiate palliative care for older adults with serious, life-limiting illness. Objective To assess the effect of a multicomponent intervention to initiate palliative care in the ED on hospital admission, subsequent health care use, and survival in older adults with serious, life-limiting illness. Design, Setting, and Participants Cluster randomized, stepped-wedge, clinical trial including patients aged 66 years or older who visited 1 of 29 EDs across the US between May 1, 2018, and December 31, 2022, had 12 months of prior Medicare enrollment, and a Gagne comorbidity score greater than 6, representing a risk of short-term mortality greater than 30%. Nursing home patients were excluded. Intervention A multicomponent intervention (the Primary Palliative Care for Emergency Medicine intervention) included (1) evidence-based multidisciplinary education; (2) simulation-based workshops on serious illness communication; (3) clinical decision support; and (4) audit and feedback for ED clinical staff. Main Outcome and Measures The primary outcome was hospital admission. The secondary outcomes included subsequent health care use and survival at 6 months. Results There were 98 922 initial ED visits during the study period (median age, 77 years [IQR, 71-84 years]; 50% were female; 13% were Black and 78% were White; and the median Gagne comorbidity score was 8 [IQR, 7-10]). The rate of hospital admission was 64.4% during the preintervention period vs 61.3% during the postintervention period (absolute difference, −3.1% [95% CI, −3.7% to −2.5%]; adjusted odds ratio [OR], 1.03 [95% CI, 0.93 to 1.14]). There was no difference in the secondary outcomes before vs after the intervention. The rate of admission to an intensive care unit was 7.8% during the preintervention period vs 6.7% during the postintervention period (adjusted OR, 0.98 [95% CI, 0.83 to 1.15]). The rate of at least 1 revisit to the ED was 34.2% during the preintervention period vs 32.2% during the postintervention period (adjusted OR, 1.00 [95% CI, 0.91 to 1.09]). The rate of hospice use was 17.7% during the preintervention period vs 17.2% during the postintervention period (adjusted OR, 1.04 [95% CI, 0.93 to 1.16]). The rate of home health use was 42.0% during the preintervention period vs 38.1% during the postintervention period (adjusted OR, 1.01 [95% CI, 0.92 to 1.10]). The rate of at least 1 hospital readmission was 41.0% during the preintervention period vs 36.6% during the postintervention period (adjusted OR, 1.01 [95% CI, 0.92 to 1.10]). The rate of death was 28.1% during the preintervention period vs 28.7% during the postintervention period (adjusted OR, 1.07 [95% CI, 0.98 to 1.18]). Conclusions and Relevance This multicomponent intervention to initiate palliative care in the ED did not have an effect on hospital admission, subsequent health care use, or short-term mortality in older adults with serious, life-limiting illness. Trial Registration ClinicalTrials.gov Identifier: NCT03424109
Unilateral Versus Bilateral Endoscopic Resection of Olfactory Neuroblastoma: Pooled Analysis From Prospective and Retrospective Multicenter Data
Abiri, Arash , Nguyen, Theodore V. , Chen, Haidee , Krippaehne, Elise , Rahman, Arifeen S. , Roozdar, Pooya, Rosvall, Brandon R., Sabbaj, Michael , Adappa, Nithin D. , Chang, Eugene H., Chang, Michael T. , Kohanski, Michael A. , Hwang, Peter H. , Lee, Jivianne T. , Patel, Zara M. , Smith, Timothy L. , Storm, Phillip B. , Wang, Marilene B. , Krippaehne, Elise , Rahman, Arifeen S , Beswick, Daniel , Chang, Michael T , Choby, Garret , Eide, Jacob G. , Douglas, Jennifer E , Hwang, Peter H , Nayak, Jayakar V , Patel, Zara , Smith, Timothy L , Snyderman, Carl H , Wang, Eric W , Kuan, Edward C , Nguyen, Theodore V , Lerner, David K. , Workman, Alan D. , Wu, Shannon S. , Adappa, Nithin D. , Beswick, Daniel M. , Chang, Eugene H., Choby, Garret , Geltzeiler, Mathew , Le, Christopher H. , Nayak, Jayakar V. , Pinheiro‐Neto, Carlos , Resnick, Adam , John, Maie A. St. , Suh, Jeffrey D.

Mayo Clinic

International Forum of Allergy & Rhinology | January 15, 2025 | Volume: 15 | Issue: 6 | Pages: 585-593

10.1002/alr.23531 | PMID 39811891 Get It

ABSTRACTBackgroundOlfactory neuroblastoma (ONB) is a rare sinonasal malignancy primarily treated with surgery. For tumors arising from the olfactory area, traditional treatment involves transcribriform resection of the anterior cranial fossa. Surgery can be performed with unilateral or bilateral resection depending on extent of involvement; however, there are currently no studies comparing outcomes between the two.MethodsProspective and retrospective data on primary ONB patients were collected from a multicenter registry involving eight academic sites. Propensity score matching (PSM) was used to create patient cohorts with similar baseline characteristics. Cox proportional hazards and Kaplan Meier analyses assessed overall survival (OS). Logistic regression assessed associations between extent of resection (unilateral versus bilateral) and tumor recurrence or postoperative cerebrospinal fluid (CSF) leak.ResultsA total of 187 ONB patients (47.6% female) with an average age of 53.6 ± 15.1 years were analyzed. Most tumors were unilateral (81.3%) and predominantly Kadish C (58.3%) or Hyams II (55.8%). Overall, 56.7% of patients underwent bilateral resection. Fifty‐four patients experienced tumor recurrence and nine had postoperative CSF leaks. Following PSM (n = 45/group), extent of resection was not associated with mortality (hazard ratio [HR] 1.73; p = 0.407) or OS (p = 0.400). There was no association between extent of resection and recurrence (odds ratio [OR] 0.90; p = 0.814) or postoperative CSF leak (OR 1.54; p = 0.647).ConclusionsFor ONB tumors where unilateral resection may be feasible and oncologically sound, the decision for unilateral versus bilateral resection showed no significant effect on survival, recurrence, or postoperative CSF leak. Oncologic outcomes may be comparable when resection is tailored to individual patient and tumor characteristics.
An X-linked long non-coding RNA, PTCHD1-AS, regulates autistic behaviors in humans and in mice
Scherer, Stephen W. , Bradley, Clarrisa A. , Ko, Sangyoon Y. , Ralph, Liam T. , D’Abate, Lia , Lee, Jinyeol, Liu, Tianyi , Wang, Junhui , Tidball, Patrick , Fan, Xiaolian, Howe, Jennifer, Alexandrova, Roumiana, Pellecchia, Giovanna , Casallo, Guillermo, Paton, Tara , Wybenga-Groot, Leanne , Rijke, Jill de , Kadia, Ashish , Salazar, Nelson Bautista , Shum, Carole, Rennie, Olivia , Reuter, Miriam S. , Hoang, Ny , Sarikaya, Ege , Selvanayagam, Thanuja , Rutherford, Annabel, Rivero-Alfaro, Natalia, Marshall, Christian R. , Scala, Marcello , Runke, Cassandra , Kearney, Hutton M. , Francis, David, Plucinicazak, Jill, Iaboni, Alana, Sjaarda, Calvin , Jain, Anjali , Frey, Brendan J., Vorstman, Jacob , Frankland, Paul W. , Scherer, Stephen W , Scala, Marcello , Tian, Meng , Lee, Jinyeol, Liu, Tianyi , Wang, Junhui , Mendes, Marla, Paton, Tara, Engchuan, Worrawat , Thiruvahindrapuram, Bhooma , Trost, Brett , Jin, Fuzi , Díaz-Mejía, J. Javier , MacDonald, Jeffrey R. , Deneault, Éric , Ross, P. Joel, Ellis, James , Georgiou, John , Amini, Aeen Ebrahim, Rivera-Alfaro, Natalia, Marshall, Christian R. , Christodoulou, John , Francis, David I. , Chung, Brian H Y, Pluciniczak, Jill, Wigby, Kristen M. , Nordahl, Christine Wu , Amaral, David Gil , Hudson, Melissa L., Guerin, Andrea, Elsabbagh, Mayada , Landa, Rebecca, Mital, Seema , Lesurf, Robert , Wilson, Michael D. , Ellegood, Jacob , Lerch, Jason P., Lee, Leo J. , Salter, Michael W. , Anagnostou, Evdokia, Collingridge, Graham L.

Mayo Clinic

No container title available | January 12, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5619348/v1 Get It

Abstract There are ~100 genes or copy number variants (CNVs) used in genetic testing for Autism Spectrum Disorder (ASD, or autism). These genes are protein-coding, and the associated phenotypes often extend beyond socio-behavioral traits seen in autism including cognitive/medical complexities, epilepsy, and ADHD. Here, we characterize 27 males with ASD through whole genome sequencing (WGS), delineating X-chromosome microdeletions that implicate the long non-coding RNA (lncRNA) PTCHD1-AS as an ASD-susceptibility gene (OR=2.56, p=0.01). Two Ptchd1-as knockout (KO) murine models, created by removing the evolutionarily conserved exon-3, show ASD-like features in males, increasing repetitive behaviors and impairing typical social behavior and communication without overt cognitive comorbidities or ADHD-like behaviors. Hippocampus-dependent synaptic function, complex learning, and locomotor activity are unaffected in KO mice. Native nuclear-enriched mouse Ptchd1-as showed sustained expression from post-natal day-7 onward in the dorsal striatum, a predominantly GABAergic brain region implicated in ASD. Multi-omics revealed transcriptomic alterations in striatal oligodendrocyte, astrocyte and neurons impacting myelination and plasticity pathways. Disrupting Ptchd1-as led to reductions in conventional Protein Kinase-C, altered Src and GSK3α/β phosphorylation, and an enhancement of synaptic plasticity (long-term potentiation and long-term depression). Together, these findings implicate striatal molecular and circuit level dysregulation via Ptchd1-as in ASD etiology.
Patient-reported outcome trajectories the first 24 months after surgery for cervical spondylotic myelopathy: a Quality Outcomes Database study
Zeitouni, Daniel , Johnson, Sarah E. , Bisson, Erica F. , Mummaneni, Praveen V., Haid, Regis W., Chan, Andrew K. , Chou, Dean , Wang, Michael Y. , Knightly, John J. , Meyer, Scott A., Gottfried, Oren N., Shaffrey, Christopher I., Virk, Michael S. , Fu, Kai-Ming, Shaffrey, Mark E., Foley, Kevin T. , Upadhyaya, Cheerag D., Potts, Eric A. , Turner, Jay D. , Uribe, Juan S. , Tumialán, Luis M. , Coric, Domagoj , Bydon, Mohamad , Asher, Anthony L. , Ibrahim, Sufyan , Mummaneni, Praveen V. , Shaffrey, Christopher I. , Fu, Kai-Ming, Park, Paul , Uribe, Juan S.

Mayo Clinic

Journal of Neurosurgery: Spine | January 10, 2025 | Volume: 42 | Issue: 4 | Pages: 500-508

10.3171/2024.9.spine24351 | PMID 39793008 Get It

OBJECTIVE Cervical spondylotic myelopathy (CSM) shows varying levels of improvement after surgical treatment. While some patients improve soon after surgery, others may take months to years to show any signs of improvement. The goal of this study was to evaluate postoperative improvement, patient-reported outcomes, and patient satisfaction up to 2 years after surgical treatment for CSM, which will help optimize the current treatment strategies and effectively manage patient expectations. METHODS This was a retrospective study of prospectively collected data using the Quality Outcomes Database. The primary outcomes of interest were achievement of the minimal clinically important difference (MCID) for the numeric rating scale for neck and arm pain, modified Japanese Orthopaedic Association, Neck Disability Index, and EQ-5D scores and postoperative satisfaction (North American Spine Society scale). Early and sustained improvement was defined as MCID achievement in at least one patient-reported outcome measure (PROM) at the 3-, 12-, and 24-month follow-ups. Transient improvement was defined as MCID achievement only at the 3-month and/or 12-month follow-up but not at the 24-month follow-up. Late improvement was defined as MCID achievement in at least one PROM only at the 24-month follow-up. RESULTS There were 630 patients included in the comparative analysis. A total of 463 (73.5%) patients achieved early and sustained improvement, 105 (16.7%) patients experienced transient improvement with subsequent decline, 25 (4.0%) patients reported late improvement, and 37 (5.9%) patients did not report any clinically meaningful improvement after surgery. Patients with an anterior approach were more likely to be in the early and sustained improvement group. African American patients (OR 2.98, 95% CI 1.14–7.76; p = 0.03) were more likely to report late improvement when compared with White patients. The overall satisfaction rate at the 24-month follow-up was 87.8%. CONCLUSIONS These findings indicate that 73.5% of patients achieve early and sustained improvement, and 87.8% of patients are satisfied with surgery 24 months postoperatively.